Tumor-induced osteomalacia in association with PTEN-negative Cowden syndrome

J. A. Berglund,R. I. Gafni,F. Wodajo,E. W. Cowen,D. El-Maouche,R. Chang,C. C. Chen,L. C. Guthrie,A. A. Molinolo,M. T. Collins

DOI: https://doi.org/10.1007/s00198-017-4372-x

2018-01-29

Osteoporosis International

Abstract:Tumor-induced osteomalacia (TIO) is a rare paraneoplastic condition in which phosphaturic mesenchymal tumors (PMTs) secrete high levels of fibroblast growth factor 23 (FGF23) into the circulation. This results in renal phosphate wasting, hypophosphatemia, muscle weakness, bone pain, and pathological fractures. Recent studies suggest that fibronectin-fibroblast growth factor receptor 1 (FN1-FGFR1) translocations may be a driver of tumorigenesis. We present a patient with TIO who also exhibited clinical findings suggestive of Cowden syndrome (CS), a rare autosomal dominant disorder characterized by numerous benign hamartomas, as well as an increased risk for multiple malignancies, such as thyroid cancer. While CS is a clinical diagnosis, most, but not all, harbor a mutation in the tumor suppressor gene PTEN. Genetic testing revealed a somatic FN1-FGFR1 translocation in the FGF23-producing tumor causing TIO; however, a germline PTEN mutation was not identified. To our knowledge, this is the first reported case of concurrent TIO and CS.

endocrinology & metabolism

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to report a rare case, namely the concurrent situation of tumor - induced osteomalacia (TIO) and Cowden syndrome (CS). This is the first known case of a patient suffering from both diseases simultaneously.

### Background Information:
- **TIO** is a rare paraneoplastic disease in which phosphaturic mesenchymal tumors (PMTs) secrete high levels of fibroblast growth factor 23 (FGF23) into the blood circulation, leading to renal phosphate loss, hypophosphatemia, muscle weakness, bone pain and pathological fractures.
- **Cowden syndrome** is a rare autosomal dominant genetic disease, characterized by multiple benign hamartomas and an increased risk of various malignant tumors, such as thyroid cancer. Most Cowden syndrome patients carry mutations in the tumor suppressor gene *PTEN*.

### Research Objectives:
- To report a rare case of concurrent TIO and Cowden syndrome.
- To explore the association between these two diseases at the molecular level, especially whether the FN1 - FGFR1 translocation found in PMT is related to the PTEN mutation in Cowden syndrome.

### Main Findings:
- The patient showed typical TIO symptoms, such as bone pain, repeated fractures, muscle spasms, etc., and blood tests showed hypophosphatemia and high FGF23 levels.
- Genetic tests showed that there was an FN1 - FGFR1 translocation in the patient's PMT, but no germline mutation of the PTEN gene was found.
- After surgical resection of the PMT, the patient's blood phosphorus and FGF23 levels quickly returned to normal, and the symptoms improved significantly.

### Discussion:
- This is the first reported case of concurrent TIO and Cowden syndrome, suggesting that there may be some association between these two diseases.
- The FN1 - FGFR1 translocation in PMT may play an important role in tumorigenesis, while this translocation was not found in Cowden - syndrome - related hamartomas, indicating different pathogenesis.
- Although no germline mutation of the PTEN gene was found in the patient, immunohistochemistry showed that the AKT pathway was activated in tumor cells, which may be related to the signal transduction mediated by the FN1 - FGFR1 translocation.

### Conclusion:
- This case provides a new perspective for understanding the potential connection between TIO and Cowden syndrome. Future research can further explore the association between these two rare diseases and their individual pathogenesis.